Over the last decade, the endocannabinoid system has emerged as a pivotal mediator of
acute and chronic liver injury, with the description of the role of CB1 and CB2 receptors and
their endogenous lipidic ligands in various aspects of liver pathophysiology. A large number
of studies have demonstrated that CB1 receptor antagonists represent an important
therapeutic target, owing to beneficial effects on lipid metabolism and in light of its
antifibrogenic properties. Unfortunately, the brain-penetrant CB1 antagonist rimonabant …